Efficacy of nivolumab plus ipilimumab in a patient with renal cell carcinoma concomitant with cardiac metastasis: A case report

Suguru Shirotake, Yuta Umezawa, Takashi Okabe, Go Kaneko, Kent Kanao, Koshiro Nishimoto, Masafumi Oyama

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Background/Aim: Patients with metastatic renal cell carcinoma (RCC) with cardiac metastasis have had poor outcomes in the era of molecular targeted therapy. There are few reported outcomes for patients with cardiac metastasis of RCC treated with immune checkpoint inhibitors (ICIs). Case Report: A 32-year-old female presented with metastatic RCC (unclassified type) with contralateral renal and cardiac metastases, as well as renal hilar lymph node metastases (cT4N2M1). An 18F-fluorodeoxyglucose (FDG) positronemission tomography (PET) computed tomographic (CT) scan was useful in diagnosing cardiac metastasis. Nivolumab plus ipilimumab achieved prominent shrinkage of almost all tumors except for one cardiac tumor. FDG-PET/CT scan also revealed the marked attenuation of FDG uptake in each tumor. In addition, a needle biopsy of the remaining primary renal tumor was pathologically observed to have no viable cancer cells. Conclusion: This successful case suggests that ICIs might provide a better outcome even for patients with cardiac metastasis of RCC, and that FDG-PET/CT scan might be useful for therapeutic assessment, as well as diagnosis.

Original languageEnglish
Pages (from-to)1475-1480
Number of pages6
JournalIn Vivo
Volume34
Issue number3
DOIs
Publication statusPublished - 06-2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General Biochemistry,Genetics and Molecular Biology
  • Pharmacology

Fingerprint

Dive into the research topics of 'Efficacy of nivolumab plus ipilimumab in a patient with renal cell carcinoma concomitant with cardiac metastasis: A case report'. Together they form a unique fingerprint.

Cite this